DOGS DIAGNOSED WITH SPLENIC HEMANGIOSARCOMA
Integrated Chinese Medicine Holdings Ltd. is sponsoring a study at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania.
The study objective:
To assess and compare the efficacy and side effects associated with the administration of I'm-Yunity®, doxorubicin, or both in combination to positively impact the lifespan and quality of life in dogs diagnosed with splenic hemangiosarcoma.
This clinical trial is the next phase of research with the I’m Yunity® supplement, comparing its effects to those of standard chemotherapy in dogs with splenic hemangiosarcoma.
In a previous study conducted at PennVet, the mushroom supplement I’m-Yunity® significantly increased survival time in dogs with splenic hemangiosarcoma. In this new trial, we will be comparing I’m-Yunity® effect on survival time and quality of life to the standard chemotherapy treatment.
Owners can choose between I’m-Yunity® treatment alone, or traditional chemotherapy for their dog. Half of the dogs in the chemotherapy group will randomly be assigned to get I’m-Yunity® along with their chemotherapy, and owners will not be told whether or not they’re receiving it. Dogs enrolled in this study will have 11 weekly visits, followed by monthly follow-up visits until the end of their life.
- Diagnosis of hemangiosarcoma following splenectomy.
- At least 4 kg. Not currently undergoing treatment for cancer.
- No other significant health concerns that are an immediate threat to life.
- Ability to administer oral medication (pills) to your dog.
Please contact the VCIC at 215-573-0302 or email@example.com for more information about this study.